Intestinal Microbiota Play an Important Role in the Treatment of Type I Diabetes in Mice With BefA Protein.
BefA protein
T1DM
inflammation
intestinal barrier
intestinal microbiota
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
06
2021
accepted:
02
09
2021
entrez:
4
10
2021
pubmed:
5
10
2021
medline:
21
10
2021
Statut:
epublish
Résumé
More and more studies have shown that the intestinal microbiota is the main factor in the pathogenesis of type 1 diabetes mellitus (T1DM). Beta cell expansion factor A (BefA) is a protein expressed by intestinal microorganisms. It has been proven to promote the proliferation of β-cells and has broad application prospects. However, as an intestinal protein, there have not been studies and reports on its application in diabetes and its mechanism of action. In this study, a T1DM model induced by multiple low-dose STZ (MLD-STZ) injections was established, and BefA protein was administered to explore its therapeutic effect in T1DM and the potential mechanism of intestinal microbiota. BefA protein significantly reduced the blood glucose, maintained the body weight, and improved the glucose tolerance of the mice. At the same time, the BefA protein significantly increased the expression of ZO-1, Occludin, and significantly reduced the expression of TLR-4, Myd88, and p-p65/p65. BefA protein significantly reduced the relative expression of pro-inflammatory cytokines IL-1β, IL-6 and TNF-α. In addition, our high-throughput sequencing shows for the first time that the good hypoglycemic effect of BefA protein is strongly related to the increase in the abundance of the beneficial gut bacteria
Identifiants
pubmed: 34604109
doi: 10.3389/fcimb.2021.719542
pmc: PMC8485065
doi:
Substances chimiques
factor A
0
Vitamin B 12
P6YC3EG204
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
719542Informations de copyright
Copyright © 2021 Qin, Chen, Li, Wei, Zhou, Le, Hu and Chen.
Déclaration de conflit d'intérêts
Author QQ was employed by company Harbin Meihua Biotechnology Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Expert Opin Drug Saf. 2006 Jan;5(1):131-43
pubmed: 16370962
Cell. 2019 Aug 8;178(4):795-806.e12
pubmed: 31398337
Eur J Nutr. 2018 Sep;57(6):2081-2090
pubmed: 28608319
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Cell Metab. 2018 Oct 2;28(4):557-572.e6
pubmed: 30017352
Discov Med. 2014 Mar;17(93):139-43
pubmed: 24641956
Lancet. 2001 Jul 21;358(9277):221-9
pubmed: 11476858
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10713-10718
pubmed: 28893978
Trends Microbiol. 2016 Jul;24(7):523-524
pubmed: 26996766
Future Med Chem. 2013 Mar;5(4):411-30
pubmed: 23495689
Intern Med. 2010;49(12):1085-7
pubmed: 20558922
Cell Metab. 2020 Jan 7;31(1):46-61
pubmed: 31839487
Metabolism. 2016 Feb;65(2):20-9
pubmed: 26773926
Nat Rev Immunol. 2020 Jan;20(1):40-54
pubmed: 31388093
Diabetes Ther. 2019 Apr;10(2):375-392
pubmed: 30661221
Diabetologia. 2016 Mar;59(3):426-35
pubmed: 26780750
Nat Rev Dis Primers. 2017 Mar 30;3:17016
pubmed: 28358037
Nat Commun. 2017 Nov 27;8(1):1785
pubmed: 29176714
Expert Opin Drug Saf. 2012 Jul;11(4):565-79
pubmed: 22616948
Lancet. 2017 Jan 28;389(10067):369-380
pubmed: 28007348
Dev Ophthalmol. 2017;60:1-5
pubmed: 28427059
Exp Diabetes Res. 2012;2012:256707
pubmed: 23346100
Diabetes Ther. 2018 Oct;9(5):1831-1851
pubmed: 30209797
Diabetes Metab Res Rev. 2018 Oct;34(7):e3043
pubmed: 29929213
Elife. 2016 Dec 13;5:
pubmed: 27960075
Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):6458-6463
pubmed: 29866843
Diabetes Res Clin Pract. 2018 Apr;138:271-281
pubmed: 29496507
Diabetes Metab. 2014 Dec;40(6 Suppl 1):S28-34
pubmed: 25554069
Gastroenterology. 2016 Oct;151(4):616-32
pubmed: 27436072
Gastroenterology. 2018 Oct;155(4):960-962
pubmed: 30201361
Lancet. 2018 Jun 16;391(10138):2449-2462
pubmed: 29916386
Lancet Diabetes Endocrinol. 2017 Jul;5(7):501-512
pubmed: 28533136
Gut Pathog. 2020 Feb 3;12:6
pubmed: 32025243
Exp Mol Med. 2018 Aug 16;50(8):1-9
pubmed: 30115904
Phys Ther. 2008 Nov;88(11):1254-64
pubmed: 18801858
J Pharmacol Sci. 2020 Jun;143(2):89-96
pubmed: 32173265
BMJ. 2017 Apr 3;357:j1321
pubmed: 28373161
Nat Rev Endocrinol. 2017 May;13(5):268-277
pubmed: 27834384
Int J Mol Sci. 2020 Feb 01;21(3):
pubmed: 32024112
Nat Microbiol. 2016 Oct 10;2:16180
pubmed: 27723761
Curr Diab Rep. 2016 Oct;16(10):89
pubmed: 27523648
Methods Mol Biol. 2020;2076:1-30
pubmed: 31586319
Lancet. 2019 Oct 5;394(10205):1265-1273
pubmed: 31533908
Endocr Pract. 2003 Nov-Dec;9(6):530-43
pubmed: 14715482